Format

Send to

Choose Destination
N Engl J Med. 2019 Feb 14;380(7):612-615. doi: 10.1056/NEJMp1900079.

Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast Cancer.

Author information

1
From the Office of Hematology and Oncology Products, Center for Drug Evaluation and Research (T.M.P., J.A.B.), and the Oncology Center of Excellence (R.P.), Food and Drug Administration, Silver Spring, and the Breast Cancer Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore (T.M.P., J.A.B.) - both in Maryland.
PMID:
30763188
DOI:
10.1056/NEJMp1900079
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center